1 / 10

Trial Selection Process

Trial Selection Process. Jingjing Zhang, et al. JAMA. 2006;296:1619-1632. Included Trials of Rofecoxib*. Jingjing Zhang, et al. JAMA. 2006;296:1619-1632. Included Trials of Celecoxib*. Jingjing Zhang, et al. JAMA. 2006;296:1619-1632. Included Trials of Valdecoxib and Parecoxib*.

eugenia-lang
Télécharger la présentation

Trial Selection Process

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Trial Selection Process Jingjing Zhang, et al. JAMA. 2006;296:1619-1632

  2. Included Trials of Rofecoxib* Jingjing Zhang, et al. JAMA. 2006;296:1619-1632

  3. Included Trials of Celecoxib* Jingjing Zhang, et al. JAMA. 2006;296:1619-1632

  4. Included Trials of Valdecoxib and Parecoxib* Jingjing Zhang, et al. JAMA. 2006;296:1619-1632

  5. Included Trials of Etoricoxib and Lumiracoxib Jingjing Zhang, et al. JAMA. 2006;296:1619-1632

  6. Descriptive Characteristics of Included Randomized Double-Blind Clinical Trials of Cyclooxygenase 2 Inhibitors Jingjing Zhang, et al. JAMA. 2006;296:1619-1632

  7. Number of Arrhythmia Events by Reported Subtypes Jingjing Zhang, et al. JAMA. 2006;296:1619-1632

  8. Overall Relative Risks of Renal and Arrhythmia Events, Cyclooxygenase 2 Inhibitors vs Controls Jingjing Zhang, et al. JAMA. 2006;296:1619-1632

  9. Relative Risk of Composite Renal Events (Renal Dysfunction, Peripheral Edema, Hypertension) by COX-2 Inhibitors, Meta-Regression Stratified by Study Characteristics Jingjing Zhang, et al. JAMA. 2006;296:1619-1632

  10. Time-Cumulative Analysis of Rofecoxib and Risk of Renal and Arrhythmia Events Sensitivity analyses of the 9 trials with 20300 participants (10126 drug, 10174 control group) and 15 arrhythmia events (13 drug, 2 control group) without half-integer correction using sparse-events exact methods: Fisher exact test P =.004, and Mantel-Haenszel pooled relative risk 6.52 (95% CI, 1.48-28.8; P=.004) Jingjing Zhang, et al. JAMA. 2006;296:1619-1632

More Related